Targeted Therapies in Urothelial Carcinoma

Download All
Learn how experts incorporate the newest targeted therapies and antibody–drug conjugates into optimal management of advanced, progressive urothelial carcinoma with downloadable slides from a live CCO Webinar.
Petros Grivas, MD, PhD
Cora N. Sternberg, MD, FACP

Downloadable Slidesets

Learn about the most clinically influential developments in leveraging immune checkpoint inhibitor–based therapy for first-line, second-line, and maintenance treatment of advanced urothelial carcinoma.

Cora N. Sternberg, MD, FACP Released: February 26, 2021

Review expert guidance on integrating erdafitinib and enfortumab vedotin into management of progressive urothelial carcinoma, then get up to date on key data for sacituzumab govitecan and other promising investigational therapies.

Petros Grivas, MD, PhD Released: February 26, 2021

Download this short summary slideset of key takeaways from a live presentation on integrating targeted agents into the management of progressive urothelial carcinoma.

Petros Grivas, MD, PhD Cora N. Sternberg, MD, FACP Released: March 11, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Immunomedics, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings